Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Identification of a possible proteomic Biomarker in Parkinson’s Disease: Discovery and Replication in Blood, brain and CSF

WINCHESTER L. and NEVADO-HOLGADO A., (2022), Brain Communications

Neurons derived from individual early Alzheimer's disease patients reflect their clinical vulnerability.

Ng B. et al, (2022), Brain Commun, 4

Genome and epigenome wide studies of plasma protein biomarkers for Alzheimer′s disease implicate TBCA and TREM2 in disease risk

Hillary RF. et al, (2021)

ANMerge: A comprehensive and accessible Alzheimer’s disease patient-level dataset

Birkenbihl C. et al, (2020)

Dysregulated Fc gamma receptor-mediated phagocytosis pathway in Alzheimer's disease: network-based gene expression analysis.

Park YH. et al, (2020), Neurobiol Aging, 88, 24 - 32

Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT

Howard R. et al, (2020), Efficacy and Mechanism Evaluation, 7, 1 - 62

Tau pathology in early Alzheimer’s disease is linked to selective disruptions in neurophysiological network dynamics

Kocagoncu E. et al, (2020), Neurobiology of Aging

Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort.

Westwood S. et al, (2020), J Alzheimers Dis, 74, 213 - 225

Will We Have a Drug for Alzheimer's Disease by 2030? The View From Pharma.

Lovestone S. and Manji HK., (2020), Clin Pharmacol Ther, 107, 79 - 81

Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial.

Howard R. et al, (2019), JAMA Neurol

Genetic and Real-World Clinical Data, Combined with Empirical Validation, Nominate Jak-Stat Signaling as a Target for Alzheimer's Disease Therapeutic Development.

Nevado-Holgado AJ. et al, (2019), Cells, 8

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease.

Ashton NJ. et al, (2019), Sci Adv, 5

MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.

Ten Kate M. et al, (2018), Alzheimers Res Ther, 10

Cross-sectional and longitudinal analyses of outdoor air pollution exposure and cognitive function in UK Biobank.

Cullen B. et al, (2018), Sci Rep, 8

Headache and type 2 diabetes association: a US national ambulatory case-control study

Nash A. et al, (2018)

Heterogeneous patterns of brain atrophy in Alzheimer's disease.

Poulakis K. et al, (2018), Neurobiol Aging, 65, 98 - 108

Elevated DNA methylation across a 48-kb region spanning the HOXA gene cluster is associated with Alzheimer's disease neuropathology.

Smith RG. et al, (2018), Alzheimers Dement

Imaging Aβ and tau in early stage Alzheimer's disease with [18F]AV45 and [18F]AV1451.

Firouzian A. et al, (2018), EJNMMI Res, 8

Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection.

Pardiñas AF. et al, (2018), Nat Genet, 50, 381 - 389

A Decade of Blood Biomarkers for Alzheimer's Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication.

Shi L. et al, (2018), J Alzheimers Dis, 62, 1181 - 1198

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?